Jun 2026 (Q2 FY26) — Jul 30, 2026
Guardant Health Q2 FY26 — Strong Growth Across Segments, Key Shield Milestones, and FDA Approvals
Read the full callGuardant Health (GH) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Guardant Health earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 335 | +44.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -38.5 | +7.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -120 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$157.88 −0.45% · −$0.72
Performance +141.2% 1Y
1Y: $65.46 on 17 Oct 2025 → $157.88. High $187.22 (5 Oct 2026), low $65.46 (17 Oct 2025).
- Previous close
- $158.6
- 52-week range
- $67.51 – $187.22
- One year
- +124.90%
Overview
- Symbol
- GH
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 7, 2026
Guardant Health Q1 FY26 — Strong Revenue Growth and Shield Momentum
Read the full callEvery analysed call
Guardant Health earnings calls (GH)
Financials
What the filings say
Net profit, year on year: −20% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 191 | 202 | 203 | 232 | 265 | 281 | 302 | 335 |
| Expenses | 309 | 328 | 315 | 339 | 364 | 402 | 423 | 464 |
| Operating profit | -117 | -126 | -111 | -106 | -99 | -121 | -121 | -129 |
| Operating margin | −61.3% | −62.4% | −54.6% | −45.9% | −37.3% | −43.0% | −40.2% | −38.5% |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | -108 | -110 | -95 | -100 | -93 | -130 | -112 | -120 |
| Tax rate | −0.0% | −0.7% | −0.3% | −0.0% | −0.1% | 1.3% | −0.3% | −0.1% |
| Net profit | -108 | -111 | -95 | -100 | -93 | -128 | -112 | -120 |
| EPS ($ per share) | -0.88 | — | -0.77 | -0.80 | -0.74 | — | -0.85 | -0.90 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Reserves | -281 | -353 | -607 | -1,008 | -1,662 | -2,142 | -2,578 | -2,995 |
| Total liabilities | 62 | 115 | 916 | 1,559 | 1,550 | 1,628 | 1,625 | 2,113 |
| Fixed assets | 31 | 44 | 63 | 124 | 168 | 145 | 137 | 146 |
| Investments | 278 | 380 | 962 | 441 | 870 | — | — | — |
| Total assets | 587 | 963 | 2,272 | 2,204 | 1,610 | 1,786 | 1,486 | 2,014 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -72 | -47 | -104 | -209 | -309 | -325 | -240 | -185 |
| Cash from investing | -153 | -318 | -617 | -63 | 150 | 840 | -261 | -627 |
| Cash from financing | 293 | 367 | 1,410 | -67 | -189 | 477 | -1 | 671 |
| Net cash flow | 68 | 3 | 690 | -341 | -350 | 992 | -504 | -140 |
| Capital expenditure | -20 | -19 | -36 | -75 | -77 | -20 | -35 | -48 |
| Free cash flow | -92 | -66 | -140 | -284 | -387 | -345 | -275 | -233 |
GH revenue by segment
| Segment | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|
| Reportable | 100% | 100% | 100% | 100% | 100% | 100% | +44.3% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
GH operating KPIs by quarter
| KPI | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Oncology test volumes | ~86KOncology test volumes rose 47% to approximately 86,000 tests, up from 59,000 in the prior year period.Source: earnings call transcript | ~104KOncology test volumes rose 63% to approximately 104,000 tests, up from 64,000 in the prior year period with strength across all products.Source: earnings call transcript | — |
| Shield tests Screening | ~44KWe delivered $42 million of Shield testing revenue driven by approximately 44,000 tests compared to $6 million revenue and approximately 9,000 tests in Q1 of 2025.Source: earnings call transcript | ~66KWe delivered $53 million of Shield testing revenue, driven by approximately 66,000 tests compared to $15 million of revenue and approximately 16,000 tests in Q2 of 2025.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Revenue by region
Q2 FY2026 · share of revenue
- Non Us 5% ↓ 1 pt
As GH cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
456 filings between Oct 21, 2025 and Oct 14, 2026.
Open market
decisions to buy or sellPurchases
$78.5K
1 purchase by 1 insider
Sales
$173.91M
143 sales by 15 insiders
38% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 231
- Option exercise — converted options into shares
- 64
- Tax withheld — shares kept back by the company to cover tax
Also filed: 11 other filings, 6 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Talasaz AmirAli | — | $84.25M | Aug 21, 2026 |
| Eltoukhy Helmy | — | $22.03M | Jun 5, 2026 |
| Freeman Chris | — | $16.92M | Aug 10, 2026 |
| Monroe Terilyn J. | — | $15.95M | Aug 12, 2026 |
| Bell Michael Brian | — | $8.81M | Jun 5, 2026 |
| CLARK IAN T | — | $6.06M | Aug 4, 2026 |
| Kalia Kumud | $78.5K | $5.91M | Sep 11, 2026 |
| Chudova Darya | — | $4.36M | Sep 15, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 14, 2026 | Azar Alex M II Director | Sale 10b5-1 plan | 69 | $11.0K |
| Oct 12, 2026 | Azar Alex M II Director | Option exercise | 137 | $0 |
| Oct 1, 2026 | Eltoukhy Helmy Co-Chief Executive Officer | Option exercise | 9,716 | $0 |
| Oct 1, 2026 | Saia John G. Chief Legal Officer | Option exercise | 1,668 | $0 |
| Oct 1, 2026 | Saia John G. Chief Legal Officer | Tax withheld | 3,706 | $647.6K |
| Oct 1, 2026 | Kalia Kumud Chief Information Officer | Option exercise | 1,084 | $0 |
| Oct 1, 2026 | Eltoukhy Helmy Co-Chief Executive Officer | Option exercise | 23,997 | $0 |
| Oct 1, 2026 | Chudova Darya Chief Technology Officer | Option exercise | 1,340 | $0 |
| Oct 1, 2026 | Chudova Darya Chief Technology Officer | Option exercise | 1,701 | $0 |
| Oct 1, 2026 | Saia John G. Chief Legal Officer | Option exercise | 974 | $0 |
| Oct 1, 2026 | Kalia Kumud Chief Information Officer | Tax withheld | 3,067 | $536.0K |
| Oct 1, 2026 | Chudova Darya Chief Technology Officer | Tax withheld | 4,320 | $754.9K |
| Oct 1, 2026 | Bell Michael Brian Chief Financial Officer | Option exercise | 1,871 | $0 |
| Oct 1, 2026 | Bell Michael Brian Chief Financial Officer | Option exercise | 3,324 | $0 |
| Oct 1, 2026 | Talasaz AmirAli Co-Chief Executive Officer | Option exercise | 23,997 | $0 |
| Oct 1, 2026 | Talasaz AmirAli Co-Chief Executive Officer | Option exercise | 9,716 | $0 |
| Oct 1, 2026 | Kalia Kumud Chief Information Officer | Option exercise | 1,607 | $0 |
| Oct 1, 2026 | Freeman Chris Chief Commercial Officer | Tax withheld | 3,143 | $549.2K |
| Oct 1, 2026 | Saia John G. Chief Legal Officer | Option exercise | 1,496 | $0 |
| Oct 1, 2026 | Chudova Darya Chief Technology Officer | Option exercise | 3,324 | $0 |
| Oct 1, 2026 | Kalia Kumud Chief Information Officer | Option exercise | 1,995 | $0 |
| Oct 1, 2026 | Monroe Terilyn J. Chief People Officer | Option exercise | 2,659 | $0 |
| Oct 1, 2026 | Chudova Darya Chief Technology Officer | Option exercise | 1,668 | $0 |
| Oct 1, 2026 | Saia John G. Chief Legal Officer | Option exercise | 2,925 | $0 |
| Oct 1, 2026 | Bell Michael Brian Chief Financial Officer | Option exercise | 2,085 | $0 |
| Oct 1, 2026 | Freeman Chris Chief Commercial Officer | Option exercise | 1,292 | $0 |
| Oct 1, 2026 | Freeman Chris Chief Commercial Officer | Option exercise | 2,527 | $0 |
| Oct 1, 2026 | Talasaz AmirAli Co-Chief Executive Officer | Tax withheld | 17,087 | $2.99M |
| Oct 1, 2026 | Freeman Chris Chief Commercial Officer | Option exercise | 1,668 | $0 |
| Oct 1, 2026 | Freeman Chris Chief Commercial Officer | Option exercise | 1,929 | $0 |
| Oct 1, 2026 | Bell Michael Brian Chief Financial Officer | Tax withheld | 3,914 | $684.0K |
| Oct 1, 2026 | Monroe Terilyn J. Chief People Officer | Option exercise | 1,360 | $0 |
| Oct 1, 2026 | Monroe Terilyn J. Chief People Officer | Tax withheld | 2,098 | $366.6K |
| Oct 1, 2026 | Kalia Kumud Chief Information Officer | Option exercise | 1,360 | $0 |
| Oct 1, 2026 | Eltoukhy Helmy Co-Chief Executive Officer | Tax withheld | 17,087 | $2.99M |
| Sep 30, 2026 | Eltoukhy Helmy Co-Chief Executive Officer | Option exercise | 2,817 | $0 |
| Sep 30, 2026 | Eltoukhy Helmy Co-Chief Executive Officer | Tax withheld | 1,428 | $254.7K |
| Sep 30, 2026 | Talasaz AmirAli Co-Chief Executive Officer | Option exercise | 2,817 | $0 |
| Sep 30, 2026 | Talasaz AmirAli Co-Chief Executive Officer | Tax withheld | 1,428 | $254.7K |
| Sep 21, 2026 | MIGNONE ROBERTO Director | Option exercise | 264 | $0 |
| Sep 17, 2026 | Hidalgo Medina Manuel Director | Option exercise | 232 | $0 |
| Sep 16, 2026 | Krognes Steve E. Director | Sale | 1,103 | $192.4K |
| Sep 16, 2026 | Krognes Steve E. Director | Sale | 3,300 | $578.9K |
| Sep 16, 2026 | Krognes Steve E. Director | Sale | 1,300 | $229.2K |
| Sep 16, 2026 | Krognes Steve E. Director | Sale | 971 | $172.3K |
| Sep 16, 2026 | Azar Alex M II Director | Sale 10b5-1 plan | 826 | $144.6K |
| Sep 16, 2026 | Tariq Musa Director | Sale 10b5-1 plan | 116 | $20.3K |
| Sep 15, 2026 | Tariq Musa Director | Option exercise 10b5-1 plan | 249 | $0 |
| Sep 15, 2026 | Chudova Darya Chief Technology Officer | Sale | 7,738 | $1.38M |
| Sep 12, 2026 | Azar Alex M II Director | Option exercise | 1,651 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Guardant Health, Inc.
Free account. Everything above stays public.
Write why you follow Guardant Health, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading